Conference
The effects of a CCR3 inhibitor, AXP1275, on allergen‐induced airway responses in adults with mild‐to‐moderate atopic asthma
Abstract
BACKGROUND: CCR3 is the cognate receptor for major human eosinophil chemoattractants from the eotaxin family of proteins that are elevated in asthma and correlate with disease severity.
OBJECTIVE: This proof-of-mechanism study examined the effect of AXP1275, an oral, small-molecule inhibitor of CCR3, on airway responses to inhaled allergen challenge.
Authors
Gauvreau GM; FitzGerald JM; Boulet LP; Watson RM; Hui L; Villineuve H; Scime TX; Schlatman AR; Obminski C; Kum J
Volume
48
Pagination
pp. 445-451
Publisher
Wiley
Publication Date
April 2018
DOI
10.1111/cea.13114
Conference proceedings
Clinical & Experimental Allergy
Issue
4
ISSN
0954-7894